These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 16483650)
1. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Hasselbalch HC; Riley CH Leuk Res; 2006 Oct; 30(10):1217-25. PubMed ID: 16483650 [TBL] [Abstract][Full Text] [Related]
2. The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders. Hasselbalch HC; Riley CH Curr Drug Targets; 2007 Feb; 8(2):247-56. PubMed ID: 17305502 [TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [TBL] [Abstract][Full Text] [Related]
4. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Tefferi A Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051 [TBL] [Abstract][Full Text] [Related]
5. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Zhan H; Spivak JL Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Thiele J; Kvasnicka HM; Vardiman J Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481 [TBL] [Abstract][Full Text] [Related]
7. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893 [TBL] [Abstract][Full Text] [Related]
8. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
9. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Elliott MA; Tefferi A Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701 [TBL] [Abstract][Full Text] [Related]
10. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Landolfi R; Di Gennaro L; Novarese L; Patrono C Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279 [TBL] [Abstract][Full Text] [Related]
15. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Kvasnicka HM; Thiele J Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612 [TBL] [Abstract][Full Text] [Related]
16. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses]. Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173 [TBL] [Abstract][Full Text] [Related]
17. The role of beta-catenin in chronic myeloproliferative disorders. Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646 [TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846 [TBL] [Abstract][Full Text] [Related]
19. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification. Kvasnicka HM; Thiele J Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877 [TBL] [Abstract][Full Text] [Related]
20. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Löfvenberg E; Wahlin A Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]